BioSpace News Archive

Global Interventional Radiology Market Insights | Forecast [2020-2030] | Industry Analysis

The corporate intelligence reports predict that the global interventional radiology market will record an excellent compound annual growth rate of 6.7 % over the forecast years i.e. 2016 to 2021.

May 16, 2022
·
10 min read
BioCapital

QIAGEN Expands Syndromic Testing Portfolio with the Launch of Higher-Capacity QIAstat-Dx Rise and Enhanced Panels

QIAGEN N.V. announced the launch of QIAstat-Dx Rise – a high-capacity version of the QIAstat-Dx automated syndromic system – and enhancements to the menu of tests for the fully integrated one-step molecular testing solution that provides results in about one hour.

May 16, 2022
·
6 min read
Atamyo Therapeutics Announces Significant Milestones for ATA-100 and ATA-200, its Gene Therapy Programs to Treat Limb-Girdle Muscular Dystrophy 2I/R9 and 2C/R5

Atamyo Therapeutics announced multiple major milestones for ATA-100 and ATA-200, its one-time gene-replacement therapies for the treatment of limb-girdle muscular dystrophy types 2I/R9 and 2C/R5, as well as the reinforcement of its management team.

May 16, 2022
·
4 min read
Business

Burning Rock Schedules First Quarter of 2022 Earnings Release on May 31, 2022

Burning Rock Biotech Limited, a company focused on the application of next generation sequencing technology in the field of precision oncology, announced that it plans to release its unaudited financial results for the first quarter of 2022 before the U.S. market opens on May 31, 2022.

May 16, 2022
·
2 min read
Philips showcases ultra-low contrast PCI solutions at EuroPCR 2022

Royal Philips, a global leader in health technology, is showcasing innovations at EuroPCR that can enable interventionists to perform ultra-low contrast percutaneous coronary intervention procedures with greater confidence and clarity.

May 16, 2022
·
6 min read
Business

Proteros Expands Oncology Collaboration and License Agreement with AstraZeneca

Proteros biostructures GmbH, an expert in integrated structure-based drug discovery, announces an expansion of its collaboration with AstraZeneca focused on the discovery and development of novel epigenetic drugs.

May 16, 2022
·
2 min read
Prota Therapeutics Achieves 51 Percent Peanut Allergy Remission Rate, First Company to Validate Significant Quality of Life Improvements Compared with Standard Care

Prota Therapeutics Pty Ltd is the first company to validate significant Health-Related Quality of Life improvements, when compared to placebo, in a Phase 2b clinical trial of oral immunotherapy PRT120, in which 51 percent of treated children aged 1-10 years achieved clinical remission.

May 16, 2022
·
4 min read
Business

PhaseBio Pharmaceuticals Reports First Quarter 2022 Financial Results and Recent Business Highlights

PhaseBio Pharmaceuticals, Inc. reported financial results for the first quarter ended March 31, 2022, and provided an update on corporate activities.

May 16, 2022
·
12 min read
Pharm Country

Rocket Pharmaceuticals Presents Positive Clinical Data from Danon Disease, Fanconi Anemia and Pyruvate Kinase Deficiency Programs at the 25th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)

Rocket Pharmaceuticals, Inc. announces positive clinical updates from its Phase 2 pivotal trial for Fanconi Anemia and Phase 1 trials for Danon Disease and Pyruvate Kinase Deficiency at the 25th Annual Meeting of the American Society of Gene and Cell Therapy.

May 16, 2022
·
12 min read
BioForest

Seagen Announces Resignation of President, Chairman & CEO Clay Siegall

Seagen Inc. announced that the Board of Directors yesterday accepted the resignation of Clay Siegall, Ph.D., as President, CEO and member of the Board of Directors.

May 16, 2022
·
4 min read